Pregnancy and Choline Intake Alter the Metabolic Use of Orally Consumed Choline in Women Consuming Deuterium Labeled Choline

Jian Yan,Allyson West,Cydne Perry,Xinyin Jiang,Leyla Yousef,Olga Malysheva,Srisatish Devapatla,Eva Pressman,Marie A. Caudill
DOI: https://doi.org/10.1096/fasebj.24.1_supplement.lb313
2010-01-01
Abstract:A 12‐week choline intervention study was conducted to investigate the effects of pregnancy and choline intake on the fate of orally consumed choline. Healthy non‐pregnant (n = 21) and pregnant women (n=27, 27wk gestation) were randomized to controlled choline intakes of either 450 (choline AI) or 900 mg/day; 350 mg/day dietary choline and either 100 or 550 mg/d supplemental choline chloride. During the last six weeks of the study, ~20% of the total choline intake was provided as deuterium labeled choline (d9‐choline). The labeling of choline and its metabolites was examined at the end of the study (wk 12) in plasma and urine. Pregnancy affected the use of dietary choline with higher concentrations of plasma d9‐choline (P = 0.008), lower concentrations of plasma d6‐dimethylglycine (d6‐DMG) (P < 0.001), and higher urinary d9‐choline excretion (P = 0.001) in pregnant women. A higher choline intake (900 vs 450 mg/d) yielded higher plasma concentrations of d9‐choline (P = 0.003), d6‐DMG (P = 0.02), and d‐9 betaine (especially in pregnant women; P= 0.002 for choline x pregnancy) as well as greater urinary d6‐DMG excretion (P = 0.006). These data show that (i) pregnancy alters the use of orally consumed choline and (ii) a choline intake level exceeding the choline AI increases the availability of labile methyl groups for one‐carbon metabolic reactions especially in pregnant women.Supported by grants from the USDA, ENC, and NCBA.
What problem does this paper attempt to address?